Herpes Simplex Virus (HSV)–Suppressive Therapy Decreases Plasma and Genital HIV‐1 Levels in HSV‐2/HIV‐1 Coinfected Women: A Randomized, Placebo‐Controlled, Cross‐Over Trial
Citations Over TimeTop 1% of 2008 papers
Abstract
A randomized cross-over trial of herpes simplex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20 Peruvian women coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) who were not on antiretroviral therapy. Plasma samples (obtained weekly) and endocervical swab specimens (obtained thrice weekly) were collected for HIV-1 RNA polymerase chain reaction. Plasma HIV-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (-0.26 log10 copies/mL, a 45% decrease [P < .001]), as was cervical HIV-1 level (-0.35 log10 copies/swab, a 55% decrease [P < .001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks(2014)391 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Near point-of-care HIV viral load testing: Uptake and utilization in suburban Yangon, Myanmar(2022)